FibroStatin is offering opportunities in GPBP technology - immune-complex-mediated glomerulonephritis and cancer
FibroStatin SL is a biotech company focused on the development of Goodpasture antigen-binding protein (GPBP) technology for research and medical purposes.
FibroStatin SL was founded in 2005 by researchers from the Centro de Investigación Príncipe Felipe (formerly Instituto de Investigaciones Citológicas) and the University of Valencia, and is located at the Scientific Park of University of Valencia.
FibroStatin SL holds exclusive intellectual property on GPBP-related technology through a number of international issued and pending patents.
FibroStatin SL is engaged with the research and development of novel diagnostic and therapeutic products for human disorders in which GPBP proteins are useful as diagnostic biomarkers or therapeutic targets. These disorders include immune-complex-mediated glomerulonephritis and cancer, where the increased expression of GPBP has been shown to have a relevant role.
Partnership & licensing
The managers of FibroStatin SL would be glad to consider proposals of collaboration and alliance with pharmaceutical and biotechnology companies interested in co-developing therapeutic or diagnostic projects focused on GPBP technology. Moreover, FibroStatin SL is open to establish licensing-out agreements of its patent portfolio and proprietary technology with companies willing to develop projects individually. Inquiries about collaborations and licensing-out should be forwarded to our Scientific Director.